Synthetic peptides representing the immunodominant structural motifs of the envelope region of human Tlymphotropic virus types I (HTLV-I) (Env-1191214 and Env-52257) and II (HTLV-lI) (Env-201#{176}2and Env-2187209) were used to develop an enzyme immunoassay that could discriminate between HTLV-l and HTLV-ll. Serum specimens from indMduals whose infections were confirmed and typed by means of the polymerase chain reaction (PCR) were used to determine the sensitivity and specificity of the new assay. When 73 PCR-confirmed HTLV-l specimens were tested with the HTLV-l peptides, the absorbance values for 71(97.3%)
disease clinics (2) . Because the two viruses may coexist in the same population, the ability to readily type the infections would help in determining the geographic reservoirs for these viruses and in establishing the epidemiologic and clinical correlates of the infections.
Until recently, the polymerase chain reaction (PCR) with type-specific amplification of HTLV gene products was the method of choice for distinguishing between HTLV-I and HTLV-il infection (2) . However, the PCR technique is cumbersome and impractical for large epidemiologic studies (2, 6) , and lymphocytes from the H'FLV-seropositive individuals are not always available for PCR analysis. Immunoassays are therefore being developed that will allow serologic differentiation between the two virus types (7) . Several immunodominant motifs in the structural proteins of HTLV-I and HTLV-il have been identified by use of synthetic peptides and recombinant proteins (7) (8) (9) (10) (11) (12) (13) (14) . Although some of these epitopes represent conserved motifs between HTLV-I and HTLV-II proteins (8, 13) , others are typespecific (7) (8) (9) (10) (11) (12) . Such type-specific peptides from single regions have been used to develop immunoassays that allow serologic discrimination between HTLV-I and HTLV-il (7,8, 11). Most of these assays depend on the use of single epitopes from the env-encoded proteins of HTLV-I and HTLV-il, with several amino acid differencesbetween the two epitopes (8, 10) . Because even a single amino acid substitution in the antibody binding domain can affect the binding of naturally occurring antibodies in HTL V-infected serum specimens (15, 16) , we hypothesized that immunodominant regions from more than one area would increase the sensitivity of detection.
To developan assay based on synthetic peptides representing multiple epitopes of HTLV proteins, we used HTLV-I-speciflc epitopes located at the central region (Env-1'91214) and the C-terminus (Env-57) of the external glycoprotein of HTLV-I (7) and HTLV-il-speciflc epitopeslocated at the N-terminus Env-20'#{176}2) and the central region (Env-2'87#{176}9) of external glycoprotein (10).
Materials and Methods

Synthetic Peptide Immunoassay
The synthetic peptides derived from the HTLV-I and Env-20'#{176}2: KKPNRQGLGYYSPSYNDP) external glycoproteins (see Figure 1) were synthesized by use of 9-fluorenyl-methyloxycarbonyl chemistry. Antibodies to these synthetic peptides were tested as described previously (7, 10 The cutoff values for both plates were calculated by adding 0.1 to the mean absorbance value for normal control sera on the respective plates. Specimens for which the absorbance was less than the cutoff values on both plates were considered nonreactive for antibodies to HTLV-I and HTh V-il. If the absorbance was higher than the cutoff value in either the HTLV-I or HTLV-il assay, Human Serum Specimens Serum specimens from 164 individuals previously shown to be seropositive for either HTLV-I or HTLV-U (n = 132) or seronegative for both viruses (n = 32) were chosen for this study. Among the HTLV-I-positive specimens, 73 were from US blood donors, 19 were from prostitutes from Peru, and 10 were from clinical patients with HAM or ATh. All the HTLV-il specimens (n = 59) and the uninfected specimens (n = 32) were from US blood donors.
Reference HTLV Antibody Tests
Serum specimens from all blood donors were initially tested for antibodies to HTLV-I or -il with a licensed enzyme immunoassay (HTLV-I EIA; Abbott Laboratories, Abbott Park, IL). Specimens that were repeatedly reactive were further tested by a Western blot (WB) assay incorporating purified recombinant
HThV-I envelope (r21) protein with a whole virus lysate derived from an HTLV-I-infected cell line, HuT-102 (Cambridge Biotech, Rockville, MD) (13), and a radioimmunoprecipitation assay based on use of a lysate from the MT-2 cell line (Cambridge Biotech). A serum specimen was considered HTLV-positive if antibody reactivity was detected to at least two different HTLV structural gene products [gag p24 and env gp46 and (or) gp6S].
PolymeraseChain Reaction
The amplification and detection of HTLV sequences by the PCR were performed with DNA specimens from HTLV-positive donors (n = 132). Two gene regions (pol and tax-rex) from each patient were amplified by PCR under conditions described previously (17).
Western BlotAnalysis
The seroreactivity of specimens to recombinant proteins was analyzed on WB strips containing recombinant r2le (representing a conserved epitope between HTLV-I and HTLV-il), rgp46' (MTA-1; representing an HTLV-I-specific epitope), and rgp46" (K-55; representing an HTLV-il-specific epitope) (Diagnostic Biotechnology, Singapore) (11, 16). The WB strips were incubated overnight at room temperature with 100-fold-diluted test sera, followed by three washes with The-buffered saline, and then incubated for 30 mm with goat antibody to human IgG conjugated with alkaline phosphatase (Bio-Rad, Richmond, CA). After three more washes, color development was attained by the addition of a substrate containing 5-bromo-4-chloro-3-indolyl phosphate and mtroblue tetrazolium (Kirkegaard & Perry, Gaithersburg, MD). The specimens were determined to be HTLV-I positive or HTLV-il positive depending on their reactivity with the recombinant enu proteins rgp46' or rgp4611, respectively.
SyntheticPeptide-BasedImmunoassay
A synthetic peptide-based immunoassay (Select-HTLV; Coulter Immunology), which allows discrimination between HTLV-I and HTLV-il seroreactivity, was performed as previously described (18).
Results
Synthetic Peptide Assay
We previously identified inununodominant structural motifs on the external glycoprotein 
J1
Control were correctly typed as HTLV-I (Table 1) . A similar analysis of PCR-conflrmed clinical specimens demonstrated that 9 of 10 (90%) were correctly typed as HTLV-I; all 19 specimens from Peruvian prostitutes were typed as HTLV-I. Of the PCR-conflrmed HTL V-il specimens, 55 of 59 (93%) had absorbances with HTLV-H-specific epitopes that were at least two times greater than the absorbances with HTLV-I-speciflc epitopes; they were therefore typed as HTLV-il (Table 1) . Of the four specimens that could not be typed, three had absorbance ratios for HTLV-Iand HThV-II-specific epitopes between 2.0 and 0.5; one specimen was negative on both the assays. Thus, the overall sensitivity of the assay for HTLV-I was 97.3% (71 of 73 specimens were correctly typed) and for HThV-il was 93% (55 of 59 specimens were correctly identified). More important, none of the specimens was wrongly classified in either of the assays, thus yielding a test specificity of 100%. In addition, three serial specimens from an HTLV-I-infected individual and another three from an HTLV-ilinfected individual, each specimen drawn 6-23 months apart, demonstrated specific reactivity with their respective peptides (data not shown).
Comparison of Serologic Typing with Other Immunoassays
Several immunoassays have recently been developed that allow serologic differentiation between HTLV-I and
HTLV-II
infection (10, 18, 19) . When we compared a commercial synthetic peptide assay (Select-HTLV) with the assay described here, we found that the two assays 5% (130 of 132) . The overall sensitivity of our peptide assay was 95.5% (126 of 132). Because none of the specimens was wrongly classified by either assay, the specificity of both assays was 100%.
DiscussIon
The development of serologic assays that can reliably differentiate between infections with HThV-I and HTLV-il has simplified seroepidemiologic studies of
HTLV-infected populations (18-20).
Most synthetic peptide-based assays depend on antibody recognition of immunodominant motifs from the structural proteins of HTLV-I and HTLV-il.
The Select-HThV assay, which includes HTLV-I-specific pl9 and HTLV-il-specific gp52hlv epitopes, is highly sensitive and specific for More recently, a modified WB assay has been developed that contains both the group-specific conserved motifs from the transmembrane protein (13) and typespecific motifs from the external glycoproteins of HTLV-I and HTLV-il (11, 12) . This assay allows simultaneous confirmation and differentiation of HTLV-I and HTL V-il infection (11) . In the present study, the recombinant protein-containing WB demonstrated a higher sensitivity of differentiation (98.5%) than did our peptide assay (95.5%). The higher sensitivity of the WB assay presumably reflects the assay configuration whereby the recombinant antigens are exposed to chemical denaturation, which may expose certain epitopes In addition to the immunogenicity of the central enu regions, the C-terminus of HTLV-I (Env-5257 and peptide V2'#{176}2) and the N-terminus of HTLV-il (Env20b02 and peptide Ob06) have been shown to contain type-specific epitopes (7, 8, 10) . Furthermore, Env-5
represents a surface-exposed epitope on the infected cells (27), although the antibodies to Env-5 neither inhibited syncytium formation nor protected against infection with HTLV-I in an experimental rabbit model for HTLV-I and -II infection (28) . Env-20 represents a neutralizing epitope, with type specificity conferred by amino acids Q91and L#{176}3 in the Env-20 epitope (29) .
Thus, these immunologically relevant epitopes provide highly sensitive and specific tools for the serologic distinction between HTLV-I and HTLV-il and should also be important in developing antibody screening assays that are based on multiple immunodominant sites in the structural proteins of both HTLV-I and HTLV-il.
